C4 Therapeutics, Inc. (CCCC)

Over the past six months, C4 Therapeutics' stock price has seen fluctuations, with an 8.45% gain on January 15, 2025, and a 15.50% increase over the past six months. However, the share price as of January 6, 2026, was $2.03, representing a decline of 47.41% from January 7, 2025. Key events impacting the stock include participation in the 8th Annual Evercore Healthcare Conference on November 25, 2025, reporting Third Quarter 2025 Financial Results on November 6, 2025, announcing the pricing of a $125 million underwritten offering on October 16, 2025, a clinical trial collaboration with Pfizer on October 1, 2025, and announcing 2025 milestones on January 14, 2025.

Information directly detailing demand seasonality for C4 Therapeutics' specific products and services is not explicitly available. Demand for its future commercialized products would primarily be driven by disease prevalence, treatment efficacy, regulatory approvals, and market access. From a stock market perspective, a "Buy Date" of May 16 and a "Sell Date" of August 4 for CCCC stock has resulted in a geometric average return of 22.79% above the S&P 500 Total Return Index.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines through targeted protein degradation science. The company aims to create orally available small molecule therapeutics for cancer and other serious diseases by degrading disease-causing proteins. Its major product candidates include Cemsidomide (CFT7455) in Phase 1/2 clinical trials for multiple myeloma and non-Hodgkin lymphomas, CFT1946 in Phase 1/2 clinical trials for melanoma, colorectal cancer, and other solid malignancies, and CFT8919 being developed for non-small cell lung cancer. C4 Therapeutics also engages in strategic partnerships with major pharmaceutical companies to advance drug candidates.

C4 Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States.

C4 Therapeutics generally maintains a positive to neutral brand reputation, with a MarketBeat media sentiment score of 0.71. Positive clinical data for cemsidomide and strategic collaborations with major pharmaceutical companies have positively impacted its reputation. The company has a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.56.

The ownership structure of C4 Therapeutics stock includes institutional, retail, and individual investors. Institutional investors hold approximately 31.67% to 54.21% of the stock, with major holders including Lynx1 Capital Management LP, Soleus Capital Management, L.P., and Orbimed Advisors Llc. Retail investors hold approximately 54.79% of the stock. Insiders own about 1.65% to 18.65% of the stock, with Marc A. Cohen being the largest individual shareholder.